KR101859486B1 - 설하용 덱스메데토미딘 조성물과 그의 사용 방법 - Google Patents

설하용 덱스메데토미딘 조성물과 그의 사용 방법 Download PDF

Info

Publication number
KR101859486B1
KR101859486B1 KR1020117027466A KR20117027466A KR101859486B1 KR 101859486 B1 KR101859486 B1 KR 101859486B1 KR 1020117027466 A KR1020117027466 A KR 1020117027466A KR 20117027466 A KR20117027466 A KR 20117027466A KR 101859486 B1 KR101859486 B1 KR 101859486B1
Authority
KR
South Korea
Prior art keywords
pain
dexmedetomidine
pharmaceutical composition
pharmaceutically acceptable
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117027466A
Other languages
English (en)
Korean (ko)
Other versions
KR20120008058A (ko
Inventor
제라딘 애니 핸우드
랜달 제로미 맥
크리스토퍼 토마스 샤르
존 조세핀 코랭
Original Assignee
레크로파마, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101859486(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 레크로파마, 인코포레이티드 filed Critical 레크로파마, 인코포레이티드
Publication of KR20120008058A publication Critical patent/KR20120008058A/ko
Application granted granted Critical
Publication of KR101859486B1 publication Critical patent/KR101859486B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0625—Mouth

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117027466A 2009-05-15 2010-05-17 설하용 덱스메데토미딘 조성물과 그의 사용 방법 Expired - Fee Related KR101859486B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17873009P 2009-05-15 2009-05-15
US61/178,730 2009-05-15
PCT/US2010/035136 WO2010132882A2 (en) 2009-05-15 2010-05-17 Sublingual dexmedetomidine compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20120008058A KR20120008058A (ko) 2012-01-25
KR101859486B1 true KR101859486B1 (ko) 2018-06-28

Family

ID=43085620

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117027466A Expired - Fee Related KR101859486B1 (ko) 2009-05-15 2010-05-17 설하용 덱스메데토미딘 조성물과 그의 사용 방법

Country Status (21)

Country Link
US (1) US20110021588A1 (enExample)
EP (2) EP2429521B1 (enExample)
JP (2) JP6172938B2 (enExample)
KR (1) KR101859486B1 (enExample)
CN (2) CN106511273A (enExample)
AU (1) AU2010248776B2 (enExample)
BR (1) BRPI1010567A2 (enExample)
CA (1) CA2762107A1 (enExample)
CL (1) CL2011002858A1 (enExample)
CO (1) CO6460767A2 (enExample)
CR (1) CR20110596A (enExample)
DO (1) DOP2011000354A (enExample)
EC (1) ECSP11011459A (enExample)
HN (1) HN2011003011A (enExample)
IL (1) IL216159A (enExample)
MX (1) MX2011011950A (enExample)
NZ (1) NZ596976A (enExample)
PE (1) PE20120713A1 (enExample)
RU (1) RU2572692C2 (enExample)
SG (1) SG175979A1 (enExample)
WO (1) WO2010132882A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792246B2 (en) 2018-06-27 2020-10-06 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11786508B2 (en) 2016-12-31 2023-10-17 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11890272B2 (en) 2019-07-19 2024-02-06 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
JP6268100B2 (ja) * 2011-12-11 2018-01-24 レクロ・ファーマ，インコーポレーテッド 鼻腔内デクスメデトミジン組成物およびその使用方法
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2865593A1 (en) * 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
CN104797252B (zh) * 2012-10-15 2016-09-21 奥赖恩公司 减轻噪音厌恶的兽医方法
EP2792352A1 (en) * 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
US20150273215A1 (en) * 2014-03-26 2015-10-01 Pacesetter, Inc. Systems and methods for assessment of pain and other parameters during trial neurostimulation
CN106456561B (zh) 2013-10-07 2020-02-28 帝国制药美国公司 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物
KR20180095732A (ko) * 2013-10-07 2018-08-27 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
HUE055565T2 (hu) * 2016-12-13 2021-11-29 Orion Corp Dexmedetomidin vagy medetomidin alkalmazása a szeparációs szorongás kezelésében kedvtelésbõl tartott állatoknál
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
US20220031664A1 (en) * 2020-07-28 2022-02-03 Melt Pharmaceuticals, Inc. Pharmaceutical compositions comprising antiemetics and alpha-2-adrenergic receptor agonists and methods of using the same for anesthesiological applications
EP4583871A1 (en) * 2022-09-11 2025-07-16 BioXcel Therapeutics, Inc. Methods for treating agitation in community settings
CN118542852B (zh) * 2024-07-30 2024-10-01 山东则正医药技术有限公司 包含经口给药的右美托咪定舌下膜组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DE10299002I1 (de) * 1990-12-05 2012-07-05 Gen Hospital Corp Verwendung von No zur Behandlung oder Praevention der Bronchokonstriktion
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US5713907A (en) * 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
HUP0103543A2 (hu) * 1998-10-02 2002-01-28 3M Innovative Properties Company Nyálkahártyán megtapadó hatóanyag bejuttató rendszerek és ezek alkalmazása állatok kezelésére
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8486972B2 (en) * 2006-01-25 2013-07-16 Insys Therapeutics, Inc. Sublingual fentanyl spray
ES2624577T3 (es) * 2006-02-13 2017-07-17 Orient Pharma (Samoa) Co. Ltd. Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea
US20080021074A1 (en) * 2006-06-29 2008-01-24 Questcor Pharmaceuticals, Inc. Pharmaceutical Compositions and Related Methods of Treatment
CN101057830A (zh) * 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anesth Analg.Vol.90, No. 3 , pp. 699-705(2000)
Br J Clin Pharmacol. Vol.56, No. 6 , pp. 691-693.(2003)
J Clin Anesth. Vol.18, No. 8 , pp. 589-593.(2006)*

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786508B2 (en) 2016-12-31 2023-10-17 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11931340B2 (en) 2016-12-31 2024-03-19 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11839604B2 (en) 2016-12-31 2023-12-12 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11559484B2 (en) 2018-06-27 2023-01-24 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11517524B2 (en) 2018-06-27 2022-12-06 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11806429B2 (en) 2018-06-27 2023-11-07 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US10792246B2 (en) 2018-06-27 2020-10-06 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11497711B2 (en) 2018-06-27 2022-11-15 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11478422B2 (en) 2018-06-27 2022-10-25 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11998529B2 (en) 2019-07-19 2024-06-04 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11890272B2 (en) 2019-07-19 2024-02-06 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US12109196B2 (en) 2019-07-19 2024-10-08 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US12090140B2 (en) 2023-01-12 2024-09-17 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11998528B1 (en) 2023-01-12 2024-06-04 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US12138247B2 (en) 2023-01-12 2024-11-12 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US12364683B2 (en) 2023-01-12 2025-07-22 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Also Published As

Publication number Publication date
CO6460767A2 (es) 2012-06-15
EP2429521A2 (en) 2012-03-21
MX2011011950A (es) 2012-02-21
HN2011003011A (es) 2014-12-01
DOP2011000354A (es) 2012-07-15
CL2011002858A1 (es) 2012-06-22
JP2012526854A (ja) 2012-11-01
CN106511273A (zh) 2017-03-22
WO2010132882A3 (en) 2011-03-31
EP3305281A1 (en) 2018-04-11
IL216159A0 (en) 2012-01-31
KR20120008058A (ko) 2012-01-25
US20110021588A1 (en) 2011-01-27
CR20110596A (es) 2012-03-26
RU2572692C2 (ru) 2016-01-20
CA2762107A1 (en) 2010-11-18
IL216159A (en) 2015-10-29
EP2429521B1 (en) 2017-10-18
ECSP11011459A (es) 2012-01-31
EP2429521A4 (en) 2013-08-21
AU2010248776A1 (en) 2012-01-12
JP6172938B2 (ja) 2017-08-02
JP2016029055A (ja) 2016-03-03
RU2011151059A (ru) 2013-06-20
PE20120713A1 (es) 2012-07-08
NZ596976A (en) 2014-05-30
WO2010132882A2 (en) 2010-11-18
SG175979A1 (en) 2011-12-29
CN102639131A (zh) 2012-08-15
BRPI1010567A2 (pt) 2016-03-15
WO2010132882A8 (en) 2011-12-29
AU2010248776B2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
KR101859486B1 (ko) 설하용 덱스메데토미딘 조성물과 그의 사용 방법
US20240261278A1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US20130072532A1 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
US8198291B2 (en) Intranasal opioid compositions
US20140079740A1 (en) Oral transmucosal adminstration forms of s-ketamine
AU775112B2 (en) Compositions and methods comprising morphine gluconate
JP2017533227A (ja) 低活動膀胱症候群を治療するための方法
MXPA06009094A (es) Formulaciones de liberacion controlada.
ES2340164T3 (es) Formulas orales de galantamina y sus aplicaciones.
HK1168302B (en) Sublingual dexmedetomidine compositions and methods of use thereof
HK1168302A (en) Sublingual dexmedetomidine compositions and methods of use thereof
Cashman Routes of administration
Kvarstein Alternative opioid patient-controlled analgesia delivery systems–transcutaneous, nasal, and others
HK1198958B (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230515

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230515